CD23 Expression in Mantle Cell Lymphoma: Clinicopathologic Features of 18 Cases

Schlette, Ellen; Fu, Kai; Medeiros, L. Jeffrey

doi:10.1309/xv4ag7emwqu7er67

Cited by 65 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 On the other hand, CD5 and CD43 expression, a common feature of MCL and CLL may also occur in MZL. 24 Finally, although CD10 or BCL-6 have not been detected in cyclin D1-negative MCL some conventional MCL may express these germinal center markers.…”

Section: Discussionmentioning

confidence: 99%

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype

Mozos¹,

Royo²,

Hartmann³

et al. 2009

Haematologica

334

280

View full text Add to dashboard Cite

BackgroundCyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas. The clinical and pathological characteristics of patients with this form of lymphoma have not been well defined. Overexpression of the transcription factor SOX11 has been observed in conventional mantle cell lymphoma. The aim of this study was to determine whether this gene is expressed in cyclin D1-negative mantle cell lymphoma and whether its detection may be useful to identify these tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype

Mozos¹,

Royo²,

Hartmann³

et al. 2009

Haematologica

334

280

View full text Add to dashboard Cite

show abstract

“…However, biologic heterogeneity includes rare CD23 Ϫ cases of CLL, whereas CD23 positivity in MCL is not uncommon. [26][27][37][38] In our test and validation cohorts, 13 of 42 (31%) cases of MCL in leukemic phase were CD23 ϩ , whereas 5 MCL cases in the test cohort had a mini-CLL score of 3. The diagnostic discriminant was useful in such cases with an atypical immunophenotype by combining the information from the CD160FCA on the mini-CLL score and the level of CD23 expression ( Figure 5C).…”

Section: Discussionmentioning

confidence: 99%

“…Although MCL is typically CD23 Ϫ , in the test cohort, 11 of 34 (32%) cases of MCL expressed CD23 (with all cases were confirmed to be MCL by G banding, FISH, and/or histology), which is similar to other reports. 26,27 In contrast, 598 of 600 ( Ͼ 99%) cases of CLL were CD23 ϩ . Because the percentage of CD23 positivity in MCL was lower than that in CLL, we investigated the ratio of the percentage of CD23 to CD5 expression on the malignant B cells (referred to as CD23r) as a parameter to differentiate CLL from CD23 ϩ MCL.…”

mentioning

confidence: 99%

Differential and tumor-specific expression of CD160 in B-cell malignancies

Farren

Giustiniani

Liu

et al. 2011

Blood

View full text Add to dashboard Cite

CD160 is a human natural killer (NK)- IntroductionCD160 is an Ig-like activating natural killer (NK) cell receptor expressed on the majority of circulating NK cells and on a subset of circulating cytotoxic T cells, but not on B cells or EBV-transformed B-cell lines. 1,2 In contrast to the majority of NK cell receptor genes located on chromosomes 12 and 19, 3 the CD160 gene is located on chromosome 1q42.3. 4 CD160 is expressed by most peripheral blood TCR␥␦ lymphocytes, a minor subset of circulating CD8 brightϩ TCR␣␤ cells, and all small intestinal intraepithelial T lymphocytes, phenotyped as CD3 ϩ TCR␣/ ␤ ϩ CD56 Ϫ . 5 A minor population of CD4 ϩ T cells also express CD160. 6 CD160 mRNA expression was shown to be highly restricted to NK cells and not detected in myeloid and B-cell lines by Northern blot analysis. 5 Outside of the immune system, CD160 is expressed on endothelial cells of neoangiogenic microvessels at the periphery of tumors. 7 NK cells play a key role in innate immunity, having potent cytolytic activity against virally infected and tumor cells. 8 NK-cell activity is regulated by inhibitory and activatory receptors expressed at the cell surface and their interaction with associated ligands. 9 CD160 binds to MHC class Ia and Ib with low affinity 10 and triggers cytotoxic function in peripheral blood NK cells, as well as cytokine production, including IFN-␥, TNF-␣, and 12 Only a limited number of human activating NK-cell receptors have been demonstrated to induce cytokine production and release in addition to cytotoxicity. 13 The PI3K signaling molecule is required for CD160-mediated cytokine release, with involvement of the signaling molecules Syk and ERK upstream and downstream of PI3K, respectively. 14 Recent work has demonstrated CD160 expression in malignant human B cells. 15 CD160 expressed on the surface of B-cell chronic lymphocytic leukemia (CLL) mimicked CD160 functions in normal NK and T cells: cellular activation, up-regulation of BCL-2 and BCL-XL , and improved in vitro cell survival and cytokine production, specifically IL-6 and IL-8. PI3K/Akt signaling was required for CD160-mediated functions in CLL cells. 15 Similar "aberrant" expression of a signaling molecule, CD3-receptor-associated protein tyrosine kinase or -associated protein-70 (ZAP-70), was reported in CLL. 16,17 Like CD160, ZAP-70 was initially described exclusively in T cells and NK cells, 18 but was subsequently detected in mature and immature human B-lymphoid malignancies, 19-21 as well as normal murine and human B cells. 22,23 In the present study, we investigated normal and malignant human B cells for expression of CD160. This extensive study established that the NK cell receptor antigen CD160 shows restricted expression in the B-cell lineage to malignant compared with normal B cells. Moreover, the varying expression of CD160 can be exploited diagnostically, as shown in test and validation sets consisting of Ͼ 970 cases of B-cell lymphoproliferative disorders (B-LPDs). Methods Patients and samplesThis study involved a t...

show abstract

“…The cell-surface phenotype of the DTG tumors is consistent with MCL-BV. 9,11,47,48 One of the characteristics of MCL-BV is the expression of bcl-1/cyclin D1. 5,9,49 We evaluated cyclin D1 expression in the tumors of the IL-14␣ TG, c-myc TG, and DTG mice.…”

Section: Blood 1 June 2007 ⅐ Volume 109 Number 11mentioning

confidence: 99%